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ABSTRACT

In the area of Quality-by-Design (QbD), the determination of process parameters or quality
attributes of a product using sufficient process analytical technology (PAT) is a crucial for the
establishment of continuous processes as a standard pharmaceutical technology, such as hot-melt
extrusion. For the purpose of the study, three different formulations were developed and design
space was evaluated with the aid of PAT, while a design of experiment (DoE) was implemented
to assess the effect of the process critical parameters and to identify the critical quality attributes
(CQA) of the extrusion processing.
Solid self-emulsifying drug delivery systems were developed instead of a conventional liquid
system. Solid surfactants was chosen to emulsify lipids with different HLB properties. Type of
surfactant, type of lipid, Lipid/surfactant L/S ratio, feed rate, screw speed and screw configuration,
were the formulation and process parameters evaluated. Solid self-emulsifying drug delivery
systems were successfully developed on the hot-melt extruder for the first time which is a
continuous processing technology.
Blends of theophylline, (HMPC K4M, Affinisol 100LV) were processed using a twin screw
extruder to investigate the effect of temperature and screw configuration on the various granule
properties. Particle size distribution was measured using Parsum probe in-line particle size
analysis. The effect of the critical process parameters to optimize the conditions or design space
to achieve the tablet with greater sustained release properties. Affinisol 100LV was proven to have
better sustained release properties and was robust with respect to the change in process parameters.
Continuous salt preparation was achieved of a poorly water soluble compound Indomethacin with
a highly water soluble co-former tromethamine. Design of experiments was used to evaluate the
effect of feed rate, screw speed, temperature on the salt properties. The effect of the different
process parameters on the extent of formation of the crystalline salt was determined using in-line
FTNIR analysis. Furthermore, the integration of the DoE experiments demonstrated that
ŝŝ


temperature and screw configuration, had a significant effect on the quality attributes. This QbD
approach was successfully employed as a paradigm for the development of pharmaceutical
formulations via HME processing.
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I. CHAPTER

INTRODUCTION
With the advent of combinatorial chemistry and high-throughput screening, the drug discovery
pipelines have witnessed extremely insoluble molecules (Lee et al., 2017). This results in low
dissolution rate and variations in the bioavailability when administered orally. Many formulation
technologies such as salt formation, cocrystallization, lipid based delivery, solid dispersion,
particle size reduction, have been used to enhance dissolution rate and oral bioavailability of such
compounds. However, there are limitations associated with respect to each of the methods. For
example in lipid based drug delivery system, there is critical balance required to be achieved to
attain complete drug solubility in formulation as well as maintain the drug in solubilized state
during dilution while dissolution in gastro-intestinal tract. Also there is a need for more reliable
rapid characterization techniques to enable early phase screening. In addition, the amount of drug
delivered in lipid based drug delivery system is limited by the solubility of the drug in that lipid,
surfactant system. With respect to salt or co-crystal formulations there is a tendency for the
individual components to be dissociated into their counter-parts (Nie et al., 2016; Qiao, Wang,
Schlindwein, Davies, & Li, 2013). Amorphous solid dispersion has been of increasing importance
in the recent years. For early development, formulation of amorphous solid dispersion is performed
using spray drying, this results in requirement of large quantity of organic solvent for dissolution
of drug and carrier. The need for solvent handling during manufacturing is increased for such
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applications. Drug precipitation due to instability and re-crystallization from the polymer matrix
is a major hurdle in the development of stable amorphous solid dispersions. (Serajuddin, 1999).
In addition to the techniques mentioned above, salt formation of acidic and basic drugs is most
common strategy for enhancement of dissolution and widely used in the pharmaceutical industry.
Salt formation is the primary method used to enhance the dissolution rate and oral bioavailability.
When salt formation is not a feasible or does not provide desired solubility then other techniques
for bioavailability enhancement are applied. Approximately, 50% of marketed drugs are
formulated as salt forms of ionizable active pharmaceutical ingredients (APIs) having acidic or
basic moieties (Berge, Bighley, & Monkhouse, 1977; Pudipeddi, Serajuddin, Grant, & Stahl,
2002).
There has also been an interest in forming Formulation of cocrystals of APIs, has also gained
significant attention in the past decade, especially when the salt formation is not feasible. However,
cocrystals do not form for most APIs. As salts could be considered as new APIs and thus have the
advantage of patent protection, hence are considered more valuable than cocrystals in development
of pharmaceuticals (Rajput, 2014; Stephenson, Aburub, & Woods, 2011).
In this study, the limitations of the formulations such as self-emulsifying drug delivery system,
sustained release tablets, salt formation by solvent driven process has been addressed. Firstly,
Attempts were made to develop a solid self-emulsifying drug delivery system which eliminates
the issues of a liquid in capsule type of a system. Secondly, with the sustained release tablet
formulations, it was proposed to develop a high drug load of melt granules which aids in suitable
lowering of tablet weight and provide sustained release for upto 18 hours. In addition, salt
formation of a poorly water soluble API was carried out in a continuous processing technique. All
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the formulations were developed on a twin screw extruder which eliminates the need of using
organic solvent for processing.
In the current research, Quality by design (QbD) and the elements of QbD are applied and its
implementation in pharmaceutics field is highlighed, including design of experiment, and process
analytical technology (PAT), are introduced for development of three different formulations.
Moreover, applications of QbD in various pharmaceutical related unit operations are summarized
and presented. A quality-by-design (QbD) approach was used to optimize the development of three
different formulations such as solid self-emulsifying drug delivery system, sustained-release tablet
and in-situ salt formation of poorly water soluble API manufactured by hot-melt extrusion (HME).
For the purpose of the study, off-line FTIR chemical imaging, in-line particle size analysis, in-line
near-infrared (NIR) spectroscopy as a process analytical technology (PAT) was explored while a
design of experiment (DoE) was implemented to assess the effect of the process critical parameters
and to identify the critical quality attributes (CQA) of the extrusion processing.
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II. CHAPTER
Applying design of experiments for investigating the impact of formulation and processing
parameters on solid self-emulsifying drug delivery systems prepared via hot-melt extrusion
technology

1. Introduction

Lipid-based formulations (LBF) have emerged as a useful formulation strategy to increase the
bioavailability of poorly water soluble drugs. Around 40% of new chemical entities present
solubility and bioavailability-related problems.
Unfortunately development of lipid-based products has been slow, which is probably due to the
perceived problems of physical and chemical instability, as well as unpredictable bioavailability
and in vivo performance of these dosage forms.
Literature presents techniques like solid dispersion, surface modification, cyclodextrin
complexation,and micellar solutions that have been developed to improve aqueous solubility of
poorly water-soluble drugs. One such technique used to improve the dispersion and enhance
solubility of lipophilic drugs is nano-emulsification (Saxena & Hussain, 2012). Nano-emulsions
(NEs) are clear, stable, isotropic mixtures of oil, water, surfactants and co surfactants. NEs provide
wide application in the area of drug delivery. Nanoemulsion have gained importance as a platform
technology is because of their high solubilization capacity for various drugs, nanosize, PGP
inhibitory effects, stability over wide range of pH and ionic media
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(Gupta, Hwang, Doshi, & Mitragotri, 2013; Sha, Yan, Wu, Li, & Fang, 2005). This results in
reproducible plasma concentration profiles and improved bioavailability of various drugs.
Delivering the NE in the form of pre-concentrates or self-nanoemulsifying drug delivery systems
(SNEDDS) in hard or soft gelatin capsules is the traditional approach. There is a tendency for the
surfactants, co-surfactants and oils present in the NE system to interact with the capsule shell and
affect its integrity (Kim, Kang, Oh, Yong, & Choi, 2012). Hence formulation of emulsions as free
flowing powders or granules is a better approach. These dry powders can be processed by solvent
evaporation, spray drying and lyophilization. However, the disadvantage with these process is that
they are batch processes and involve use of organic solvents. When administered orally these dry
emulsion powders or solid emulsions will get converted back to the emulsions in gastric fluid.
Solid nano-emulsions (SMEs) can be formulated by adsorption of SNEDDS on one or more
carriers (Gumaste et al., 2013). Solid carrier provides the surface area for adsorption of the oil and
surfactant droplets and also contributes the bulk to the SMEs. Due to the advantage of solid
SMEDDS ability to be blended with excipients or converted into tablets, pellets and filled in
capsules they are preferred choice (Balakrishnan et al., 2009; Bari, Doijad, More, & Disouza,
2011). The rational design of lipid formulations requires a better understanding of formulation and
manufacturing variables that may affect the quality of the products. Meeting specific objectives of
the product and process performance characteristics have to be designed scientifically and not
merely empirically derived from performance of test batches. The rational co-incides with the
‘quality-by-design’ principle that has been promoted by the FDA. Ideally, from the selection of
drug substance, polymorphic form, and excipients, to the design, manufacturing and controls of
the produc, the approaches can be applied to all phases of pharmaceutical development.

5

This research work has focused on evaluating the feasibility of formulating solid SNEDDS using
hot melt extrusion technology and focus on the details of the formulation and manufacturing
variables of solid self-nanoemulsifying drug delivery system (Bahloul, Lassoued, & Sfar, 2014).
Previous research has demonstrated the use of conventional formulation techniques of SNEDDS
which has inherent shortcomings such as batch size manufacturing, non-uniformity of content,
liquid form of SNEDDS, stability, leakage from capsule shell (Dixit & Nagarsenker, 2010) (Cole,
Cadé, & Benameur, 2008). The present work has addressed these challenges by careful selection
of solid surfactants which act as the emulsifier as well as solid carrier thereby negating additional
burden of polymer as carrier. Also a systematic study (response surface model) has been designed
to evaluate the effect of formulation variables and process variables of hot-melt extrusion
processing.
2. Materials
Fenofibrate was purchased from Ria International (East Hanover, NJ, USA) chemicals and was
used as model BCS class II drug. Different lipids and surfactants such as Labrafac®PG, Capryo®90,
Labrasol®, Gellucire®44/14 were generously gifted by Gattefosse (USA) and Lutrol®F68,
Lutrol®F127, Kolliphor®TPGS by BASF chemicals (New Jersey, USA). HPLC-grade organic
solvents such as methanol was obtained from Fisher Scientific (USA).
3. Methods
3.1 Screening of lipids and surfactants
3.1.1 Solubility of fenofibrate in lipid and surfactant
Lipids were selected from different chemical class with wide range of HLB values (Figure 1,2).
Excess fenofibrate was weighed and added to 5ml of lipids and 500mg surfactants. Solubility
6

studies were conducted by placing an excess amount of fenofibrate in scintillation vials containing
approximately 5–7 g of vehicles independently. The mixture was then shaken in a water bath at
25°C for 24 h. The shaking time of 24 h was set because preliminary experiments showed that the
solutions reached equilibrium within 12 h and there was no further change in concentration when
shaking was continued for 24 h and longer. The supernatant was withdrawn, filtered through 0.45μm polypropylene membrane filter and diluted with acetonitrile for HPLC analysis. A Waters High
performance liquid chromatography (HPLC) system equipped with a Water 600 binary pump,
Waters 2489 UV/detector, and Waters 717 plus auto-sampler (Waters Technologies Corporation,
Milford, USA) and a Phenomenex Luna 5um C18 (2) 250 x 4.6 mm column (Torrance, CA, USA)
were used at a detection wavelength of 288 nm. The mobile phase consisted of acetonitrile and
water at a ratio of 80:20% (v/v). The mobile phase flow rate was maintained at 1.0mL/min. and an
injection volume of was 10 μL was used HPLC data was analyzed using Empower V. software
(Milford, MA, USA)(Patel, Li, & Serajuddin, 2016; Shah & Serajuddin, 2012).

Labrafil®M1944 (HLB 9) Oleoyl polyoxyl-6-glycerides

Capryol®90 (HLB 5) Propylene glycol monocaprylate
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Labrasol® (HLB 12) Caprylocaproyl polyoxyl-8-glycerides

Labrafac®PG (HLB 1) Propylene glycol dicaprylate
Figure 1: Structure of Lipids used in the formulations

Surfactant name

Surfactant chemical name

HLB

Lutrol F68

Poloxamer 188

24

Polyoxyethylene-polyoxypropylene block
copolymer (Ratio 80:27)
Lutrol F127

Poloxamer 407

18

Polyoxyethylene-polyoxypropylene block
copolymer (Ratio 101:56)
Gellucire®44/14

Lauroyl polyoxyl-32 glycerides

11

Kolliphor®TPGS

(D-α- Tocopherol polyethylene glycol)

13

Figure 2: Surfactants used in the formulation
3.1.2 Dispersion study
8

Solid SNEDDS were evaluated for their ability to disperse into globules of size <200nm in suitable
dissolution medium. Labrafac®PG (HLB 1) and Capryol®90(HLB 5) were chosen as the lipids due
to higher solubility of fenofibrate in the lipids and Lutrol F68 and Lutrol F127 were selected as
the solid surfactant system. Fenofibrate was loaded in the lipids upto 90% of its solubility in order
to avoid precipitation due to saturation. Two different lipid:surfactant ratios were chosen of 50:50
and 60:40 to test the dispersion efficiency in Fasted state Simulated Gastric Fluid (FaSSGF).
4.1.3 In-vitro dissolution
The in-vitro dissolution of the both the ratios formulated with the lipids and surfactants were
evaluated using USP type II apparatus in 250ml of simulated FaSSGF at 37°C. The formulations
were incorporated into a dialysis bag and placing 5ml of media into the dialysis unit and clipped
using dialysis bag sealer. Samples were withdrawn at 5, 15, 30, 60, 120mins.
3.2 Feasibility of preparation of solid SNEDDS
3.2.1 Preparation of solid SNEDDS by conventional technique- Melt sonication
Fenofibrate loaded solid SNEDDS were prepared conventionally by melt probe sonication
technique. Liquid lipid such as Labrafac®PG, Capryol®90 were chosen as the desired lipid for the
formulation. Two different solid surfactant such as Lutrol®F68 and Lutrol®F127 were selected for
the formulation. Fenofibrate was pre-dissolved in the lipid upto 90% its solubility. The lipid and
solid surfactant were mixed in different ratios of 50:50 and 60:40 respectively as shown in table 2
and 3. The drug loaded lipid solution was mixed with the solid surfactant and heated upto 70°C so
that solid surfactants were completed melted. At this temperature the mixture was sonicated on an
Ultrasonicator for 5mins.
3.2.2 Preparation of modified Labrafac®PG Solid SNEDDS
9

The previous mentioned formulation of Labrafac®PG formulation was modified where 50% of the
total incorporated solid surfactant was replaced with Kolliphor®TPGS and Gellucire®44/14 as cosurfactants (Table 4).
3.2.3 Preparation of solid SNEDDS by hot melt extrusion
Solid self nano-emulsifying drug delivery (S-SNEDDS) systems of fenofibrate were formulated
by twin screw extrusion process using Process 11, Thermo Fisher Scientific®. The solid surfactants
were fed from the hopper, whereas the lipid was added from third zone of extruder. The extrusion
was carried out at 100 rpm and 7% feed rate (1.9 g/min) (Table 6). The temperature of extrusion
process was kept as 65°C (Zone1-4), 45°C (zone 5-6) and 30°C (zone 7-8). Initial temperature of
operation assured complete melting of the solid surfactants, while gradual cooling towards the end
was carried to avoid separation of surfactant and lipid matrix once the product exits the extruder.
Two different screw configurations were evaluated for its effect on obtaining the desired product
characteristics whose schematic representation is shown in Figure 3 (A) (B).
3.3 Design of experiments
A response surface (optimal) design was adopted to study the effect of critical process parameters
and formulation variables on the product characteristics. Optimal design is one of the most
commonly used designs of the experiment. They are the resolution five designs, so they can be
used to study the main effects and interactions between variables to be investigated. The processing
input variables studied were feed rate (4-8 g/min), screw speed (100- 200 rpm), screw
configuration (impact of one kneading block v/s two) (Figure 3A and 8B); while the formulation
variables were Ratio of Lipid to Surfactant (0.5-1 L/S ratio), type of lipid (HLB 5, 9, 12), type of
surfactant used (HLB 18, 24). A total of 41 experimental trials with a response surface design were
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constructed using design expert stat-ease software version 9 to study the six variables (Table 1).
Multilinear regression analysis was performed to test the significance of the model and the factor
coefficients. The experimental runs (formulations) were prepared in triplicate. The dependent
variables were In-vitro dissolution (Y1), average particle size (Y3), poly-dispersity index (Y4).
The linear equation of the model is as follows:
Y = b0 + b1X1 + b2X2 + b3X3 + b4X4 + b5X5 + bnXn…
where Y is the response, b0 is the constant, and b1,..bn is the coefficient of factor X1,…Xn.
Run A: Feed
rate
No.
g/min

B: Screw C: Ratio
speed rpm of L/S

D: Screw
E: Type of
configuration lipid (L) HLB

F: Type of
surfactant (S)
HLB

1

5.11

115

0.68

1

5

24

2

6.02

200

0.85

1

5

24

3

8.00

100

0.80

1

5

24

4

5.40

169

0.96

1

5

24

5

6.61

110

0.50

1

5

18

6

5.60

166

0.72

1

5

18

7

8.00

176

0.50

1

9

24

8

8.00

176

1.00

1

9

24

9

5.40

100

0.96

1

9

24

10

5.11

100

0.68

1

9

24

11

4.00

200

0.50

1

9

18

12

7.32

145

0.50

1

9

18

13

7.73

100

0.96

1

9

18

14

4.00

121

0.50

1

12

24

15

8.00

200

0.64

1

12

24

11

16

5.60

174

0.72

1

12

24

17

4.00

156

0.80

1

12

24

18

6.25

200

0.58

1

12

18

19

6.02

121

0.85

1

12

24

20

4.00

165

1.00

1

12

18

21

8.00

200

0.78

1

12

18

22

6.00

100

0.95

1

12

18

23

4.75

183

1.00

2

5

24

24

8.00

133

1.00

2

5

24

25

4.00

200

1.00

2

5

18

26

4.88

100

0.50

2

5

18

27

6.48

200

0.51

2

5

18

28

4.00

200

0.50

2

5

18

29

8.00

183

1.00

2

5

24

30

7.98

117

0.53

2

9

24

31

4.00

200

0.50

2

9

24

32

8.00

154

0.50

2

9

24

33

4.55

145

1.00

2

9

18

34

5.51

200

1.00

2

9

18

35

4.00

145

0.62

2

9

18

36

8.00

100

0.88

2

9

18

37

4.22

100

0.50

2

12

24

38

6.25

198

0.58

2

12

24

39

7.14

145

0.63

2

12

18

40

4.00

150

0.79

2

12

18

41

8.00

100

0.99

2

12

18

Table 1: Response surface design of experiments (Design Expert®)
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Figure 3 (A): Screw configuration 1 (2kneading blocks), 11mm twin screw extruder Thermo
Scientific®

Figure 3 (B): Screw configuration 2 (1kneading block), 11mm twin screw extruder Thermo
Scientific®
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3.4 Characterization of conventional and hot-melt extruded formulations
The extruded formulations were compared to the conventionally prepared ones by melt sonication
technique. The S-SNEDDS prepared were analyzed for percent drug dissolved in media by
Dissolution testing using dialysis bag, physical state of drug in formulation by Differential
Scanning Calorimetry, Content Uniformity by FTIR Chemical Imaging, Globule size of dispersed
emulsion.
3.4.1 Differential Scanning Calorimetry
DSC studies were performed with a Perkin Elmer Diamond differential scanning calorimeter
(DSC) equipped with Pyris software (Shelton, CT, USA). Samples were prepared by sealing 3-5
mg of pure API, physical mixtures, blank formulations, drug loaded extrudates in hermetically
sealed aluminum pans and heated from the temperature range of 30°C to 100°C at the heating rate
of 20°C/min under an inert nitrogen atmosphere at a flow rate of 20 mL/min.
3.4.2 Fourier transforms infrared spectroscopy (FTIR)
FTIR spectra of the API, lipids, surfactants and milled extrudates were recorded using an Agilent
Cary 660 FTIR spectrophotometer (Santa Clara, CA, USA) to investigate any possible interactions
between the drug, polymer and other excipients. The infrared images were produced by taking
spectral derivatives of the obtained spectra and isolating spectral bands representative of
fenofibrate alone. Images were taken to study the uniformity of distribution of fenofibrate in the
formulation.
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3.4.3 Content Uniformity
In addition to evaluating the content uniformity via chemical imaging, the content of fenofibrate
in formulation was analyzed by assaying a measured quantity using HPLC reverse phase analysis.
About 50mg of the formulations were weighed and dissolved in methanol to dissolve the API. The
extracted methanolic solution was suitably diluted to be analyzed via reverse phase HPLC. The
content uniformity was evaluated using Waters HPLC-UV system (Water Corporation) and a Luna
5μm C18 column at 285nm.
Content Uniformity ratio = Actual drug loading/ Expected drug loading.
When the content uniformity ratio was close to 1 implied that the actual and expected drug loading
was similar. When content uniformity ratio was >1 it implied that the actual drug loading was
higher than expected, whereas when it was <1 it implied that the actual drug loading was lesser
than expected.
3.4.4 Dispersion testing and globule size analysis
To simulate the degree and efficiency of emulsification of lipids in GI fluids after oral
administration of the solid systems developed, the dispersion test was conducted by using the USP
apparatus II (paddle method; Distek Inc., NJ, USA) at 50 RPM and 37°C with 250 ml of simulated
FaSSGF as the dispersion medium. Since the aqueous solubility of the drug fenofibrate was pHindependent and all lipids and solid systems were non-ionic, the medium did not affect the release
of the drug. Since the solid dosage form after oral administration encounters an acidic environment
in the stomach FaSSGF was chosen as the medium.
A volume of 250 ml was selected for the dispersion test to mimic the gastric fluid volume as per
the Biopharmaceutical Classification System after oral administration of solid dosage unit.
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Approximately 200mg of the formulation was directly added to the dispersion vessel using
weighing boats. To evaluate the effect of drug loading, if any, on emulsification properties of solid
systems, controls without drugs were also subjected to dispersion test. Thus, the dispersion test for
a particular formulation was conducted six times, three with drug and three without drug. Both
drug concentration and particle size of dispersion fluids were analyzed for formulations with drugs,
while only particle sizes of oil globules were measured for drug-free systems. Aliquots from
dispersion vessels were withdrawn at 5, 15, 30, 45, 60, 90, 120 min time points. Particle sizes were
measured without any dilution. The mean particle size and polydispersity index (PDI) of the
developed solid SNEDDS were determined by using Zetasizer Nano ZS (Malvern, USA).
Dynamic light scattering technique was used to measure particle size. This technique measures the
diffusion of particles moving under Brownian motion and converts this to size and a size
distribution using the Stokes-Einstein relationship.
3.4.5 In-vitro dissolution
All the formulations (conventional and hot-melt extruded) were evaluated for the in-vitro drug
dissolution profile. 100mg of formulation was weighed and filled into dialysis bag (MWCO
100,000 daltons, pore size 4nm). About 5ml of dissolution medium was added to the dialysis bag.
The dialysis bag was placed in the dissolution medium containing FaSSGF. The dissolution testing
was performed using type II dissolution apparatus. The use of dialysis method ensured that only
fenofibrate solubilizing in the gastric fluid was analyzed and not the lipid micelle globules. The
samples were taken at different time intervals of 5, 15, 30, 60, 120mins and analyzed for
fenofibrate content using reverse phase HPLC.
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4. Results and Discussion
4.1 Screening study to evaluate SNEDDS formation
4.1.1 Dispersion study
Solid SNEDDS were evaluated for their ability to disperse into globules of size <200nm. Labrafac®
PG (HLB 1) and Capryol®90(HLB 5) were chosen as the lipids due to higher solubility of
fenofibrate in the lipids (Table 2) and Lutrol®F68 and Lutrol®F127 were selected as the solid
surfactant system. Fenofibrate was loaded in the lipids upto 90% of its solubility in order to avoid
precipitation due to saturation. Two different lipid: surfactant ratios were chosen (50:50 and 60:40)
to test the dispersion efficiency.
Lipid and surfactant

HLB Solubility (mg/ml)

Capryol®90

5

112.93

Labrafac®PG

1

94.34

Labrafil®M1944

9

57.2

Labrasol®

12

92.01

Lutrol ®F68

24

Lutrol ®F127

18

Kolliphor® TPGS

13

Gellucire® 44/14

11

< 50 µg/ml

Table 2: Solubility data for fenofibrate in different lipids
All the evaluated ratios of the different lipid and surfactant (conventional) formulations were found
to have particle size of <200nm. From Table 3, 4 it can be seen that Capryol®90 has particle size
lesser than Labrafac®PG. Labrafac®PG has greater hydrophobic groups as compared to Capryol®
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90, hence stabilizing the lipid micelle is a challenge. Due to this, certain co-surfactants such as
Kolliphor®TPGS and Gellucire®44/14 with lower HLB compared to the existing Lutrol®
surfactants. were added at a concentration of 50% of the initial surfactant which is depicted in
Table 5. As seen in figure 4 the particle size of modified Labrafac®PG solid SNEDDS dispersed
in the gastro intestinal fluids displayed smaller globule size than the original solid SNEDDS
formulation. This can possibly be due to stabilization of the globule with additional hydrophobic
chains of the co-surfactant. Kolliphor®TPGS provided the better stability to the formulation as
compared to Gellucire®44/14.
Formulation

Lipid

Surfactant

(Ratio of lipid:
surfactant)

Average particle size (nm)

L-1

Labrafac®PG

Lutrol® F68

(50:50)

150

L-2

Labrafac®PG

Lutrol® F68

(60:40)

161

L-3

Labrafac®PG

Lutrol® F127

(50:50)

186

L-4

Labrafac®PG

Lutrol® F127

(60:40)

174

Table 3: Dispersion test and particle size measurement of conventionally prepared SNEDDS of
Capryol® 90

Formulation

Lipid

Surfactant

C-1

Capryol®90

Lutrol® F68

(50:50)

108

C-2

Capryol®90

Lutrol® F68

(60:40)

102

C-3

Capryol®90

Lutrol® F127

(50:50)

147

C-4

Capryol®90

Lutrol® F127

(60:40)

118

(Ratio of lipid:
surfactant)

Average particle
size (nm)

Table 4: Dispersion test and particle size measurement on conventionally prepared SNEDDS of
Labrafac®PG
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Formulation

Lipid (50%)

Co-Surfactant (25%)

Surfactant (25%)

SNEDDS-1

Labrafac®PG

Kolliphor®TPGS

Lutrol®F68

SNEDDS-2

Labrafac®PG

Gellucire®44/14

Lutrol®F68

Table 5: Labrafac®PG SNEDDS modified formulation with co-surfactant
Conventional

HME formulation

Formulation
SNEDDS- 1

HME- 1

SNEDDS- 2

HME- 2

C1

HME- 3

C2

HME- 4

C3

HME- 5

C4

HME- 6

Table 6: Conventional formulation and their respective hot-melt extruded formulation denotation
The particle size of hot-melt extruded modified Labrafac®PG formulations (Figure 5) compared
to the conventional formulations was significantly lesser due to increased shear intensive mixing
that could be achieved during extrusion and better molecular miscibility between the solid
surfactants, co-surfactants and lipids. Also better content uniformity of the hot melt extruded
formulations was one of the reasons. This was also shown with respect to Capryol®90 solid
SNEDDS extruded formulations (Figure 6).
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Figure 4: Particle size of modified Labrafac®PG SNEDDS (conventional method)
80

HME 2

70

HME 1

60
50
40
30
20
10
0
5

15

30
45
Time (min)

60

120

Figure 5: Particle size of modified Labrafac®PG SNEDDS (hot-melt extrusion method)

20

120

Particle size (nm)

100
HME-3
80
HME-4
60
HME-5
40
HME-6
20
0
5min

15min

30min

45min

60min

90min

120min

Time

Figure 6: Particle size of Capryol®90 SNEDDS dispersed formulations (hot –melt extruded)

4.1.2 In-vitro dissolution
In-vitro dissolution of Labrafac®PG SNEDDS formulation (Figure 7), did not result in complete
dissolution of API into the FaSSGF medium. All the ratios of 50:50 and 60:40 only resulted in the
25-35% drug dissolved at the end of 2 hours. Due to larger particle size of the Labrafac®PG
globules, the total specific surface area available was smaller. Hence, the formulation was
modified to incorporate co-surfactants to decrease the globule size and hence increase the area
available for dissolution.
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Figure 7: In-vitro dissolution test for Labrafac®PG SNEDDS (conventional method)
From the plot of %in-vitro dissolution of modified Labrafac®PG, it was seen that the release
increased upto 45% for Gellucire®44/14 formulations and 68% for Kolliphor® TPGS at the end of
2 hours. Inspite of the change in formulation composition, significant increase in dissolution was

% Fenofibrate dispersed

not achieved with conventional melt sonicated solid SNEDDS formulations (Figure 8).
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Figure 8: In-vitro dissolution test for modified Labrafac®PG SNEDDS (conventional method)
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The hot-melt extruded formulations achieved significantly higher drug release (65% and 85%) as
compared to the conventional ones as noted from Figure 9. Although Labrafac®PG extruded
formulations attained greater release as compared to conventional ones, complete 100% release
was not attained. This can be due to higher affinity of drug for the hydrophobic lipid and poor

% Fenofibrate dissolved

release from the lipid into the dissolution medium.
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Figure 9: In-vitro dissolution test for modified Labrafac®PG SNEDDS (hot-melt extrusion
method)
Hence, Capryol®90 a lipid with higher hydrophilicity (HLB) was chosen for the formulation. From
Figure 10, it can be seen that greater than 85% drug release was obtained in the first 15min of the
study. This was attributed to lesser affinity of the drug to the lipid and better diffusion into the
medium.
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Figure 10: In-vitro dissolution test for modified Capryol®90 SNEDDS (hot-melt extrusion method)
4.1.3 Differential Scanning Calorimetry
The physical state of fenofibrate in the formulation was evaluated using a differential scanning
calorimeter (Pyris®DSC) to evaluate re-crystallization. Figure 11 (A), (B), (C) demonstrates the
Differential Scanning thermograms of physical mixture of formulation components; blank and
fenofibrate loaded hot-melt extruded formulations. Fenofibrate has a melting point of 87°C and
the solid surfactants used in the formulations melt between 45-55°C. It could be inferred that
fenofibrate was in amorphous or solubilized state in the hot melt extruded formulations. From
Figure 11 A the physically mixed formulations demonstrate the crystalline state of fenofibrate.
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Figure 11 (A): DSC thermograms of physical mixtures of fenofibrate, lipid and surfactant

Figure 11 (B): DSC thermograms of hot-melt extruded blank formulations

25

Figure 11 (C): DSC thermograms of hot-melt extruded fenofibrate loaded formulations
4.1.4 Fourier Transform Infra-red Spectroscopy and Imaging
Figure 12 shows the FTIR spectra’s of pure components incorporated into the modified Labrafac®
PG formulations. At a wavenumber (1650 cm-1) corresponding to only fenofibrate complete 3D
imaging was performed to evaluate content uniformity of the drug in conventional and hot-melt
extruded formulations. From Figure 13 (A) (B) corresponding to SNEDDS-1 and SNEDDS-2
(conventional) it can be seen that the distribution was very non-uniform where high concentrations
of drug (red area) was seen at the edges of the sample as opposed to Figure 14 (A) (B)
corresponding to HME-1 and HME-2. In the latter case fenofibrate was seen uniformly distributed
throughout the sample specimen. Uniform distribution of the API can be attributed to homogenous
distribution of lipid inside the solid surfactant matrix, as the drug has solubility only in the lipid
and negligible solubility if the surfactant. During the second half of the hot-melt extrusion process
where the temperature was gradually reduced below the melting temperature of the solid
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surfactants, solidification was observed. During this solidification, homogenous blending between
lipid and surfactant was provided by the kneading blocks of the extruder, which was not available
in the conventional method. In the conventional method, as the formulation cooled, there was
separation due to solidification of surfactant.
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Figure 12: FTIR spectra of formulation excipients
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(A) SNEDDS-1

(B) SNEDDS-2

Figure 13: FTIR Chemical Images of modified Labrafac®PG SNEDDS (conventional)

(A) HME-1

(B) HME-2

Figure 14: FTIR Chemical Imaging Spectra of modified Labrafac®PG SNEDDS (hot-melt
extruded)
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4.2 Evaluation of DOE response surface model
4.2.1 Effect on in-vitro dissolution rate
The type of lipid and surfactant chosen for formulation significantly impacted the dissolution rate
of the formulations as shown in Figure 15, 16. Formulations with Lutrol®F68 suggested higher
dissolution rate compared to those with Lutrol®F127. This can be attributed to higher hydrophilic
groups in Lutrol®F68 which can efficiently form micelles of a smaller size compared to those with
Lutrol®F127 and result in greater surface area available for dissolution into the media. All three
lipids had greater than 85% drug dissolved within 15mins. Relatively Labrafil® M1944 had higher
dissolution rate compared to both Capryol®90 and Labrasol®. This was possibly due to lower drug
loading of 1.7-2.5%w/w that could be achieved in Labrafil®M1944 compared to 3.5-5.06%w/w in
Capryol®90 and 2.7-4.15% w/w in Labrasol®. Hence, there was twice the amount of surfactant
available for solid SNEDDS formulation in Labrafil®M1944 as compared to those in Capryol®90
and Labrasol®. The Pareto chart plot for effect of different variables on the in-vitro dissolution is
shown in figure 15. The type of lipid and surfactant were the two main factors which influenced
dissolution rate significantly (p<0.05). The interactions between the parameters did not
significantly influence the in-vitro dissolution rate.
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Figure 15: Pareto Chart to study the impact of input variables on In-vitro dissolution rate

Figure 16: 3D plot for influence of input variables on In-vitro dissolution rate
4.2.2 Effect on Content Uniformity
The type of surfactant significantly impacted the uniformity of distribution of API. Lutrol®F127
is reported to have higher melt viscosity as compared to Lutrol®F68 (Kocbek, Baumgartner, &
Kristl, 2006; Schilling & McGinity, 2010; Schmolka, 1977). Hence formulations with Lutrol®F68
had good content uniformity as compared to those with Lutrol®F127 due to better dispersion effect
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in the kneading zone. Figure 18 (A) and (B) it can be noted that formulation with screw
configuration 1 and Lutrol®F68 had the content uniformity ratio approximately 1 and those with
screw configuration 2 and Lutrol®F68 was significantly greater than 1. This implies that a
minimum of two kneading blocks (screw configuration 1) was essential in the formulation of
uniform dispersion of lipid into the surfactant matrix. From the pareto chart (Figure 17) it is noted
that the type of lipid also significantly impacted the content uniformity. Formulations with
Capryol®90 and Labrasol® had content uniformity ratio close to 1 (1.002, 1.06) whereas for
Labrafil®M1944 it was significantly different (0.7).

Figure 17: Pareto Chart to study the impact of input variables on content uniformity of extrudates
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Figure 18 (A): 3D plot for influence of input variables on content uniformity (Feed rate 4g/min,
Screw speed 200rpm, L/S ratio 0.60, Screw configuration 1)

Figure 18 (B): 3D plot for influence of input variables on content uniformity (Feed rate 4g/min,
Screw speed 200rpm, L/S ratio 0.60, Screw configuration 2)
4.2.3 Effect on Particle size
The particle size of the globules was significantly impacted by the type of the lipid and screw
configuration. Formulations manufactured with screw configuration 1 had significantly smaller
particle size as compared to the ones with screw configuration (Figure 20). The greater the intensity
of shear incorporated due to screw configuration 1 aided in greater molecular dispersion of the
surfactant with the lipid and hence resulted in a finer globule size. The pareto chart (Figure 19)
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indicates the type of lipid to have significant influence on the globule size. The smallest globule
size was achieved by formulations with Capryol®90.

Figure 19: Pareto Chart to study the impact of input variables on particle size of SNEDDS
dispersion

Figure 20: 3D plot for influence of input variables on particle size (Feed rate 4g/min, Screw speed
200rpm, L/S ratio 0.60, Type of surfactant Lutrol®F68)
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4.2.4 Effect on Poly-dispersity index
The polydispersity index (PDI) of the dispersed globules of the solid self nano-emulsifying
systems was significantly impacted by the type of lipid incorporated in the formulation (Figure
21). The PDI was lower for formulations with Capryol®90 due to its lower HLB value as compared
to Labrafil®M1944 and Labrasol® (Figure 22). The optimum HLB of Capryol®90 ensured the
solubility of fenofibrate in the lipid globule and after dispersion in the media ensured gradual
dissolution of API from the relatively smaller and stable micelle. In case of Labrafil®M1944 and
Labrasol® lipids, due to their higher HLB, had greater preferred miscibility in water which resulted
in unstable micellar structure.

Figure 21: Pareto Chart to study the impact of input variables on PDI of particles from SNEDDS
dispersion
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Figure 22: 3D plot for influence of input variables on PDI of particles from SNEDDS dispersion
4.2.5 Desirability index
The desired or optimum process and formulation parameters were plotted from Design Expert
software (Figure 23) which resulted in higher value of in-vitro dissolution (Y1), content uniformity
ratio equivalent to 1 (Y2), lowest possible globule size (Y3) and Lowest poly-dispersity index
(Y4). The optimum process conditions (desirability of 0.9) were 4g/min feed rate, 200rpm screw
speed, Screw configuration 1, Lipid/Surfactant (L/S) 0.6, Capryol®90 as the lipid and Lutrol®F68
as the surfactant to attain >90% in-vitro dissolution, Content Uniformity ratio of 1.02, Particle size
of 44nm and PDI of 0.189.
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Figure 23: Desirability Index 3D plot for optimized formulation and processing conditions

5. Conclusion
Hot-melt extrusion was shown as a feasible and preferred process for manufacturing solid
SNEDDS. Increased residence time of formulation due to low feed rate, higher shearing action
imparted by the screw configuration and high screw speed was desired to manufacture solid
SNEDDS with desired product characteristics. Lipid such as Capryol®90 with the appropriate
balance of hydrophilic and hydrophobic groups was desired to be formulated into solid
SNEDDS. Lutrol®F68 was suitable over Lutrol®F127 due to less melt viscosity of Lutrol®F68.
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III. CHAPTER
Impact of formulation and process parameters in twin screw hot-melt granulation coupled
with in-line particle size analysis of sustained release HPMC granules
1. Introduction
Twin screw granulation is currently being explored as a continuous manufacturing technology over
batch type processes such as high shear granulation and fluid bed granulation. Development of
sustained-release oral formulations over period of 12 h usually requires release-modifying
polymers at the level of above 50% of the total weight (Vasanthavada et al., 2011). The aim of the
current investigation was to reduce the use of release modifying polymer content in production of
melt granules. This was done by focusing on the manufacturing aspects of processes to generate
desirable quality of product. The processing conditions of the polymers (Affinisol®100LV and
Methocel®100 LV) were established using hydrophilic (Xylitol) and hydrophobic (stearic acid)
plasticizing agents. Theophylline was chosen as the model API having high water solubility
(7.36mg/ml) and high melting point (273°C). Very few reports are available in the literature
describing screw configuration for hot melt granules. In this study the different screw
configurations to provide melt granules were systematically investigated (Mu & Thompson, 2012).
For a continuous processing technology such as twin screw melt granulation, establishing quality
by design is important to evaluate the impact that the process change has on the granule properties
such as in-line particle size.
The Parsum probe IPP80® (Malverrn Instruments) was used to measures particle size distributions
of the granules coming from the extruder (Figure 28).
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Figure 24: Schematic of melt granulation process coupled with Parsum Probe IPP80® for granule
size distribution measurement

Figure 25: Schematic representation of Parsum Probe IPP80® for granule size measurements
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The probe uses a patented spatial filter technique which as been developed and enhanced by
Parsum (Figure 29). The Parsum probe contains an array of light-sensitive detectors which are
illuminated by a laser. This array can detect single particles as they pass through the laser beam
within the probe measurement zone. The shadow produced by each particle can be used to calculate
the particle velocity and its chord length (particle size). The probe is capable of measuring the
particles in the size range of 50µm- 6000 µm. The detector signals are sampled very rapidly, with
sampling rates reaching several thousand particles per second. This ensures that a realistic number
of particles is measured, giving confidence that the results reported are representative of the
material within the process. The results from each particle are collected into a first-infirst-out
buffer and are used for calculating a particle size distribution. The particle size distribution data is
continuously updated during operation of the probe, providing a real time particle size trend. This
provides direct insight into the performance of the process. The technique would present
significant advantage over the conventional seive analysis which is limited by sampling a limited
quantity from the entire extruded granule batch. Hence analysis is dependent on sampling
technique.
The purpose of our work is listed in brief below:
Aim 1: Development of sustained release melt granules with a high drug load of 77%, by melt
granulation using a twin-screw extruder.
Aim 2: Investigate the effect of processing temperature and screw configurations on the
development of sustained-release melt granules.
Aim 3: Utilize an in-line particle size probe as a PAT tool to monitor the particle size distribution.
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2. Materials
Methocel 100LV, Affinisol were received as gift samples from Colorcon (PA, USA), Stearic acid
xylitol, HPLC solvents and vials were purchased from Fisher Scientific (USA).
3. Methods
Theophylline granules with high drug loading (77%) were prepared using a twin screw melt
granulation process in a 16mm (Thermo Scientific® Prism Eurolab) extruder. Design Expert® was
used to develop a response surface model (p< 0.05) and evaluate the effects of both processing and
formulation variables of HPMC grades. Affinisol® 100LV and Methocel®100 LV (HPMC 100LV)
having a tg of 130°C and 180°C, respectively, were employed as release modifying polymers.
Table 7 depicts the formulation details of the extruded granule and tablets.
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Role of ingredient

Name

API
Release modifying
polymer
API
Release modifying
polymer
Melt binder
API
Release modifying
polymer
Melt binder
Granules

Concentration %

F1 Granules
Theophylline

77

Affinisol ®100LV

23

F2 Granules
Theophylline

77

Amount
(mg)

Methocel® 100LV

20.7

Stearic acid
F3 Granules
Theophylline

2.3

Methocel® 100LV

20.7

Xylitol

2.3

Tablets
F1/F2/F3 granules

70

175

77

Lubricant

Magnesium
stearate

1

2.5

Tablet filler

Microcrystalline
cellulose

29

72.5

100

250

Total

Table 7: Details of granule and tablet formulation

Three different screw configurations (SC) were used to study the impact of the number of kneading
blocks and the presence of distributive mixing elements (DME) on the particle size distribution
(PSD) of granules; where SC1 (2 kneading blocks), SC2 (2 kneading blocks + 1 DME) and SC3
(1 kneading block + 1 DME) are depicted in Figure 30.
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Figure 26: Schematic representation of different screw configurations 16mm Prism Eurolab®
twin screw extruder Thermo Scientific®

DSC analysis was performed to screen stearic acid and xylitol as plasticizers to process
Methocel®100LV. Affinisol®100LV a highly substituted form of HPMC 100LV and manufactured
to reduce the operating extrusion temperature. Theophylline (77% w/w) was blended with
Affinisol®100LV or Methocel®100LV with melt binders as shown in Table 7 using a V-shell
blender (Globe- Pharma, Maxi blend™ New Brunswick, NJ) for 20 min at 25 rpm, after passing
through US# 35 mesh screen to remove any aggregates that may have formed. Response surface
design (optimal) was used for generating the design points (Table 8) and Design Expert software
was used for analyzing the data. Thus, the three different variables studied were temperature of
extrusion, screw configuration, Formulation (Affinisol®100LV/Methocel®100LV with 10%
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stearic acid/ Methocel®100LV with 10% xylitol as release modifying polymer). The obtained
granules were milled using a Fitz mill sieve size 40 at 4000rpm. Extra-granular excipients such as
magnesium stearate (1%) and Microcrystalline cellulose were added to the milled granules and
blended using a V-blender for 10mins. This blend was then compressed into tablets of 250mg
using a 10mm circular die and punch on a single station tablet press (tablet drug loading 70%).

Run
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Factor 1
A:Temperature
1
-1
-1
-1
1
1
1
-1
1
-1
1
1
-1
-1
-1
-1
1
1

Factor 2
B: Screw
configuration
1
1
2
1
2
2
2
3
3
1
3
3
3
2
3
2
1
1

Factor 3
C: Formulation
Affinisol® 100LV
Methocel 100 LV ® 10% Xylitol
Methocel 100 LV ® 10% Xylitol
Methocel 100 LV ® 10% Stearic acid
Affinisol® 100LV
Methocel 100 LV ® 10% Stearic acid
Methocel 100 LV ® 10% Xylitol
Methocel 100 LV ® 10% Xylitol
Methocel 100 LV ® 10% Stearic acid
Affinisol® 100LV
Methocel 100 LV ® 10% Xylitol
Affinisol® 100LV
Affinisol® 100LV
Affinisol® 100LV
Methocel 100 LV ® 10% Stearic acid
Methocel 100 LV ® 10% Stearic acid
Methocel 100 LV ® 10% Stearic acid
Methocel 100 LV ® 10% Xylitol

Table 8: Response surface design of experiments (Design Expert®)
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3.1 Granule and tablet Characterization
3.1.1 Differential Scanning Calorimetry
Pre-formulation evaluation was performed using Differential Scanning calorimetry (TA DSC25)
testing of physical blend of 10% stearic acid and 10% xylitol with Methocel®100LV. About 58mg of samples were weighed into aluminum T-zero® pans and heat cycle was run from 30°C200°C at a rate of 20°C/min. The glass transition temperature of these physical blends was
calculated using Trios 4.2.1 software.

3.1.2 Milled granule flowability
The granules were characterized for flowability, strength, in-line particle size, and surface
morphology.
Carr’s index and Hausner’s ratio were calculated to estimate the flowability of the granules. Bulk
density was calculated by measuring the volume of 5 g granules in a 10 ml graduated cylinder.
The cylinder was tapped 100 times until no further reduction in the volume of the granules was
observed. Tapped density was calculated using the volume of the granules after tapping (Patil,
Tiwari, Upadhye, Vladyka, & Repka, 2015).
Carr’s Index = Tap density – Bulk density/ Tap density X 100
Hausner’s ratio = Tap density/ Bulk density
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3.1.3 Scanning Electron Microscopy
The intact granules were evaluated for their surface texture using Scanning Electron microscopy.
The

surface

morphology

was

investigated

using

a

JEOL

6300F

scanning

electron microscope (JEOL, Tokyo, Japan) operated at 5 keV. The samples were mounted on an
aluminum board using a double-sided adhesive tape and sputter coated with gold using a sputter
coater. A scanning electron microscope operated at various magnifications was used for samples
analysis.
3.1.4 Particle Size Analysis (In-line Parsum Probe®)
Parsum Probe IPP®80 (Malvern Instruments) was used to analyze particle size in real time and
data was processed using a Log Analyzer macro. Buffer size of 500 was selected from optimization
of probe for particle size measurement. Particle probe loading was 30% and data was logged in
every 2 secs. Real time particle size distribution data were collected by the Parsum Runtime V8.01
software processed by the Log Analyzer Macro.
3.1.5 Granule Porosity
The milled granules were characterized for the percentage porosity using Micromeritics GeoPyc
Envelope density analyzer. The weighed sample was placed in a bed of DryFlo, and the DryFlo is
agitated and gently consolidated about the sample. The GeoPyc collected the displacement data,
performed the calculations and reported the percentage porosity. The true density value obtained
from the Accu-pyc helium pycnometer (Micromeritrics) was entered into Geopyc for percentage
porosity calculation.
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3.1.6 Granule Strength
In addition, milled granule strength was evaluated using TA2i Texture Analyzer (Texture
Technologies) in compression mode between parallel platens. Prior to measurement, granules were
maintained in a humidity-controlled box at room temperature and 25% RH for 48 h. The granules
size range that formed the maximum (>80%) portion of the sample were crushed using the Texture
Analyzer. Each granule was positioned in the center of a flat testing platform, and a flat-tipped
cylindrical stainless steel probe of 3 mm in diameter and 28.26 mm2 (A) in area was used to apply
the load. The probe traveled at 0.1 mm/s and penetrated a distance of approximately 0.5 mm in the
sample. Once the predetermined distance was reached, the probe was automatically withdrawn at
0.1 mm/s. Data (force vs. displacement) were collected at a rate of 250 points per second by
Texture Expert Exceed software for further analysis. The measurement was repeated 10 times for
each set of granules. During each measurement, the total force F at breakage and the diameter of
the granule dg were determined. Assuming the granule cross-sectional area to be circular in the
plane of the punch, the compression strength (σ) was calculated (Bika, Tardos, Panmai, Farber, &
Michaels, 2005).
σ = F/A
3.1.7 Tablet Hardness
Tablets were characterized for hardness and in-vitro dissolution. Ten tablets were randomly
selected and tested for their hardness (Hardness tester, Schleuniger). An additional ten tablets were
randomly selected and tested for their thickness using a digital Vernier caliper (Montana).

3.1.8 Tablet In-vitro dissolution
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In- vitro drug release was measured using USP dissolution apparatus II set at 50 rpm and 37°C.
The test dissolution media were 700 ml of 0.1N HCl (pH 1.2) for the first 2 h, then 200 ml of 0.2
M tribasic sodium phosphate (pH 12.5) to provide a final pH of 6.8 for 24 h (media were
maintained at 37 °C) to simulate the tablet transit from stomach (pH 1.2) to the intestine (pH 6.8).
The drug release studies were conducted in triplicates and the mean values were plotted versus
time. A Waters High performance liquid chromatography (HPLC) system equipped with a Water
600 binary pump, Waters 2489 UV/detector, and Waters 717 plus auto-sampler (Waters
Technologies Corporation, Milford, USA) and a Phenomenex Luna 5um C18 (2) 250 x 4.6 mm
column (Torrance, CA, USA) were used at a detection wavelength of 254 nm. The mobile phase
consisted of Methanol and water at a ratio of 35:64:1 (v/v). The mobile phase flow rate was
maintained at 1.0mL/min. and an injection volume of was 10 μL was used HPLC data was
analyzed using Empower V. software (Milford, MA, USA) (Park, Lee, Kang, Tiwari, & Repka,
2017).
4. Results and Discussion
4.1 Differential Scanning Calorimetry
Figure 31 depicts the tg of Affinisol®100 LV to be 120°C. Also, stearic acid and xylitol melted at
60°C and 70°C respectively and reduced the tg of Methocel®100LV to 140°C. Hence
Affinisol®100 LV was granulated at temperatures below 120°C, whereas a plasticizing melt
granulating agent such as stearic acid and xylitol were used to process Methocel®100LV at a
temperature below 180°C (tg). The melt binders acted as plasticizing agents to reduce the tg of
Methocel®100LV to 140°C.
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Figure 27: Differential Sanning Calorimetry thermograms of the extruded polymers with melt
binders
4.2 Particle Size Analysis (In-line Parsum Probe®)
Parsum Probe IPP®80 data suggested that particle size of granules prepared using
Affinisol®100LV was more uniform than those prepared with Methocel®100LV. From Figure 32
(A) (B) (C), the D10, D50 and D90 3D plots, it can be inferred that the granules formed with
SC3>SC1>SC2.

48

(A)

(B)

(C)
Figure 28: 3D plot for influence of screw configuration and formulation variable on particle size
(A) D10 (B) D50 (C) D90
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This can also be represented by the number of kneading blocks and the presence of distributive
elements (DME). The addition of the second mixing block towards the end in SC1 and SC2
resulted in particle size breakage as opposed to the presence of the first kneading block in the start
in all of the screw design which was critical in formation of granules. On comparison of the order
of particle size, the presence of second kneading block was more critical to particle size reduction
than the presence of distributive element (DME) as D50 from SC1<SC3. The granules prepared
from SC3 were more uniform or homogenous due to breakage due to deformation of the pellet
from all sides whereas the materials extruded with SC1, SC2 demonstrate a larger mass loss during
crushing and chipping occurring in between the kneading elements and between the kneading
element and the barrel wall. From Figure 33 (A) (B) (C) it can be confirmed that the screw
configuration variable was of most significant impact (p<0.05).

(A)

50

(B)

(C)
Figure 29: Pareto chart for influence of input variables on particle size
(A) D10 (B) D50 (C) D90

4.3 Scanning Electron Microscopy
The particle morphology observed from SEM analysis showed uniform, compact and smooth
surface granules for Affinisol®100LV in Figure 34 (A) (B), compared to non-uniform, rough
surface granules for Methocel®100LV in Figure 34 (C) (D).
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The surface of compact

Affinisol®100LV granules will lower the diffusion of water into the matrix structure as opposed
to rough and size reduced granule structure of Methocel®100LV granules which might aid in
diffusion of water into the matrix of polymer. Figure 34 (E), (F), (G) show the structure of pure
polymers and theophylline. Affinisol®100LV had more rounded particles, which are better to
compress as opposed to crystalline particles of Methocel®100LV.

(A)

(C)

(B)

(D)
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(E)

(F)

(G)

(H)

(I)

Figure 30: SEM Images of granules processed at higher temperature and SC3 formulation
(A)&(B) Affinisol® 100LV theophylline granules (x25, x100); (C) & (D) Methocel®100LV
with 10% stearic acid theophylline granules (x25, x100) (E)& (F) Methocel®100LV with 10%
xylitol theophylline granules (x25, x100) (G) Pure Affinisol® 100LV (H) Pure
Methocel®100LV (I) Pure theophylline
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4.4 Milled granule flowability
Granule flowability and compactability affects the die filling and tablet mechanical characteristics;
therefore, it is essential to study the granule flow properties. Various tests have been performed on
all formulations such as bulk density, tapped density, Carr’s index and Hausner’s ratio. According
to the flow property classification of USP, granules should have a Carr’s index between 10.0 and
18.0%, whereas Hausner’s ratio should be less than 1.25. When the Carr’s index and Hausner’s
ratio are adequate, the powder flows at minimum bulk density and consolidates to maximum
density inside the die, prior to compression. Carr’s index was observed to be higher for
unprocessed physical blends of HPMC and theophylline (45%) compared to the HME processed
granules (12.7%), which indicated better flowability of the granules. Specifically, from figure 38
Carr’s index was seen to be impacted due to the formulation type and the temperature of operation.
Methocel®100LV granules had higher Carr’s index at lower temperature and lower Carr’s index
at higher temperature Figure 37 (A) (B) (C). Carr’s index of Affinisol®100LV granules did not
vary significantly with the change of extrusion temperature. In general, formulations made with
SC3 did not vary with the formulation type or temperature, except Methocel®100LV stearic acid
granules which had higher Carr’s index at lower temperature due lesser strength and size of
granules due to cutting action of the DME. The Hausner’s ratio also followed the same trend as
the Carr’s index (Figure 35, 36).
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(A)

(B)

(C)
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Figure 31: Impact of process and formulation variables on Hausner’s ratio (A) Screw
confguration 1 (B) Screw configuration 2 (C) Screw configuration 3 (Methocel® 100LV with
10% stearic acid , Methocel® 100LV with 10% xylitol , Affinisol® 100LV )

Figure 32: Pareto chart for influence of input variables on Hausner’s ratio

(A)
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(B)

(C)
Figure 33: Impact of temperature on Carr’s index of different formulations
(A) Screw confguration 1 (B) Screw configuration 2 (C) Screw configuration 3
(Methocel®100LV with 10% stearic acid , Methocel®100LV with 10% xylitol ,
Affinisol®100LV )
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Figure 34: Pareto chart for influence of input variables on Carr’s index
4.5 Compression strength
The granule strength was impacted significantly (p<0.05) by formulation type (Figure 40). The
granules prepared with Methocel®100LV and xylitol had significantly greater strength compared
to Methocel®100LV and stearic acid (Figure 39). This was due to lesser viscosity of xylitol
compared to stearic acid and hence better spreadability over greater surface area and form greater
bridges between powder particles. The properties of granules prepared from higher temperature of
operation (tg of polymer) within the same formulation had higher strength compared to lower
temperature (melt temperature of melt binder) as greater amount of granulation was observed in
the former case, which increased the strength of solid bridges formed. Affinisol®100LV polymer
was rubbery at both the temperatures where all the polymer particles were activated as opposed to
Methocel®100LV at lower temperature only the melt binder attracts additional polymer and API
powder. Hence Affinisol®100LV had higher strength than Methocel®100LV formulations.
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Figure 35: One factor- Plot of influence of formuation variables on strength (N/mm2) of granules

Figure 36: Pareto chart for influence of input variables on strength of granules (N/mm2)
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4.6 Percentage porosity
The formulation, temperature and screw configuration, all had significant impact on the percentage
porosity as seen in the Pareto chart in Figure 42. Affinisol®100LV formulation, did not have
significant difference in percent porosity at different temperature or different screw configuration
(Figure 41A). Methocel®100 LV with stearic acid had lower percent porosity as compared to
Affinisol®100 LV as the granules with Methocel®100 LV were easily size reduced due to low
strength in the processing whereas Affinisol®100 LV had higher granule size due to greater
strength and retained their basic structure. The pores inside the Affinisol®100 LV granules were
hence retained while the Methocel®100 LV granules due to size reduction and particle breakage
had reduced pores (Figure 41 B). All of the Methocel®100 LV with xylitol formulation had similar
porosity as Methocel®100 LV with stearic acid except the one with SC3 due to least reduction of
particle size and hence the pores in that formulation (Figure 41 C).

(A)

60

(B)

(C)
Figure 37: % Porosity of the granules (A) Affinisol®100LV (B) Methocel®100LV with 10%
stearic acid (C) Methocel®100LV with 10% xylitol (SC1 , SC2 , SC3 )

61

Figure 38: Pareto chart for influence of input variables on percent porosity

4.7 Tablet hardness
The hardness of tablets prepared from Methocel®100LV granules was dependent on the extrusion
temperature and formulation type (Figure 44). The tablets prepared from Methocel®100LV
granules using stearic acid had higher hardness at lower temperature and lower hardness at higher
temperature (Figure 43A). The hardness of tablets prepared from Affinisol®100LV granules were
independent of temperature and screw configuration (Figure 43C).
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Figure 39: Effect of process variables on Hardness of tablet (SC1 , SC2 , SC3 )
(A) Methocel®100LV with 10% stearic acid (B) Methocel®100LV with 10% xylitol
(C) Affinisol®100LV
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Figure 40: Pareto chart for evaluation of main effects and interaction between input variables on
hardness of tablet

4.8 In-vitro Tablet dissolution
Percent drug dissolved was one of the output parameters investigated, where percent of drug
dissolved at the end of 12 hours was plotted. Dissolution profiles revealed sustained release
behavior for 12-16 h, which was dependent on formulation significantly (Figure 47).
Affinisol®100LV granules exhibited the highest sustained release profile followed by
Methocel®100LV granules using stearic acid and Methocel®100LV granules with xylitol (Figure
45). It was observed all granule formulations (except Methocel®100LV + xylitol) extruded at lower
temperatures using SC3, exhibited lower in-vitro release in 12h (73%) (Figure 46). Xylitol acted
as a pore former which increased the diffusion of drug into the dissolution matrix. The dissolution
profile was pH independent for all formulations.
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Figure 41: One factor- Impact of formulation variables on the in-vitro dissolution rate

Figure 42: Interaction plot- Impact of formulation variables and screw configuration on the invitro dissolution rate (SC1 , SC2 , SC3 ) (A) Low temperature (B) High temperature

Figure 43: Pareto chart for evaluation of main effects and interaction between input variables on
in-vitro dissolution of tablet
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4.9 Desirability index
The desired or optimum process and formulation parameters were plotted (Figure 48) from Design
Expert® software which resulted in lowest value of in-vitro dissolution (Y1), low Carr’s index and
Hausner’s ratio (Y2), high granule strength (Y3), unimodal granule size distribution (Y4), high
hardness (Y5). The optimum process conditions (desirability of 0.75) were Screw configuration 3,
Affinisol®100LV as release modifying polymer, higher (120°C) temperature of extrusion to
achieve <80% in-vitro dissolution in 12 hours, Carr’s index of 9, Hausner’s ratio of 1.1, granule
size distribution of 800-2000 µm, granule strength of 10478 N/mm2 and tablet hardness of 8.

Figure 44: Desirability index plot for optimal processing
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5. Conclusion
Particle size of granules depended on screw configuration (p<0.05) and reduced with addition of
2nd mixing block and DME. SC3 resulted in producing uniform and larger granules. Parsum probe
IPP®80 in-line particle size analyzer was successfully applied as a PAT tool to study the impact of
processing and formulation parameters on twin screw melt granulation processes. The
understanding of the geometric aspects of the screw elements and their effect on the maximum
size of granules from a real time particle size analysis probe in a twin Screw Granulator is a step
towards tailored granule size distributions. By choosing a certain type and design of the screw
elements, the breakage mechanisms in the granulator can be modified resulting in broad monomodal or bimodal granule size distributions. Affinisol®100LV holds greater promise to serve as a
sustained release polymer matrix with 70% drug loading to achieve release over 18hrs. Also, the
granule properties of the Affinisol®100LV granules did not vary significantly with changing
process parameters and delivered the desired output.
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IV. CHAPTER
Monitoring the molecular interaction of Indomethacin with co-former during hot-melt
extrusion using in-line FT-NIR for enhancing dissolution rate of poorly water soluble
compound

1. Introduction
With the advent of combinatorial chemistry and high throughput screening, most of the newly
synthesized small molecules in the drug discovery pipelines have been extremely insoluble in
aqueous media. As a consequence, they have low dissolution rates and exhibit poor and variable
bioavailability after oral administration to animals and humans. Many enabling methodologies,
including salt formation, co-crystallization, particle size reduction, lipid-based delivery, and
amorphous solid dispersion, have been employed to enhance dissolution rate and oral
bioavailability of such compounds (Aakeröy, Fasulo, & Desper, 2007; Pudlas et al., 2015).
However, each of these methodologies has its own limitations. In recent years, there has also been
much interest in amorphous solid dispersions. At the early stage of drug development, amorphous
solid dispersions are usually prepared by spray drying, which requires large volumes of organic
solvents to simultaneously dissolve drug and carrier, thus creating solvent handling issues during
manufacturing. The physical instability due to recrystallization of the drug from, solubilized or
amorphous state, is also a major issue for the amorphous solid dispersion (Qian, Huang, & Hussain,
2010). Salt formation of these poorly water soluble moieties is an excellent method to overcome
such disadvantages. However, the manufacture of salts on relatively large scales remains a
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complex process. Commonly used manufacturing techniques for salt formation require very large
volumes of organic solvents and high temperatures to dissolve drugs and salt forming agents,
enable chemical reaction, and obtain salts in crystalline states. Moreover, these are batch processes
rather than continuous ones. Since salts may be considered as new APIs and thus enjoy patent
protection, they are considered more valuable than co-crystals in pharmaceutical development.
Salts are generally prepared by acid–base reaction in relatively large volumes of organic solvents,
followed by crystallization (Lee et al., 2017). In this study, the potential for preparing a
pharmaceutical salt between Indomethacin (Indo) (water solubility 0.9 µg/ml, pKa 4.5) and
Tromethamine (Tro) (highly water soluble, pKa 8.1) by a novel solvent-free method using a twinscrew melt extruder was investigated. In-addition, the continuous preparation of the salt was
monitored via an in-line FT-NIR probe to determine the extrusion conditions that result in
complete interaction between the weakly acidic API and basic co-former to obtain a crystalline
salt. The pH–solubility relationship between Indo and Tro in aqueous medium was first
determined, which demonstrated that 1:1 salt formation between them was feasible (pHmax 8.1; salt
solubility 19.3 mg/mL). Salts were also prepared by solution crystallization from 200 proof
ethanol and compared with those obtained by melt extrusion.
2. Materials
Indomethacin (C19H16ClNO4, ≥ 98% purity, MW: 357.79 g/mol, M.P. 162°C, pKa 4.5) was
purchased from Combi-Blocks, Inc. (San Diego, California). Tromethamine (C4H11NO3, ≥99%
purity, MW: 121.136g/mol, M.P. 142°C (metastable polymorph) 171°C (stable polymorph), pKa
8.07) was obtained from AK Scientific, Inc. (Union City, California). All organic solvents and
other chemicals used were of analytical reagent grade from Fisher Scientific (Waltham,
Massachusetts).
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3. Methods
3.1 FTIR spectroscopy
Spectra were obtained using an attenuated total reflectance (ATR) accessory (single reflection
germanium crystal) and a DLaTGS detector. The resolution was 4 cm−1, and 32 scans were
acquired in the range of 4000–400 cm−1. The peak positions were determined using Resolutions
Pro software peak picking function.
3.2 X-ray Diffraction
Morphology of the powder samples was investigated using a Benchtop X-ray diffraction
instrument; Model Miniflex 600 (Rigaku, Woodlands, TX) with primary monochromated radiation
(CuK radiation source, λ = 1.54056 A°). The instrument was operated at an accelerating voltage
of 40 kV and 15 mA. All samples were subjected to the same program; scanned over a 2h range
of 5–40° 2θ at a step size of 0.04° 2θ/s, a dwell time of 2 s and scan speed of 1°/min.
3.3 Differential Scanning Calorimetry (DSC)
DSC studies were performed with a TA Instruments (Q25) differential scanning calorimeter (DSC)
equipped with Trios software. Samples were prepared by sealing 5-7 mg of pure API, physical
mixtures, blank formulations, drug loaded extrudates in non- hermetically sealed aluminum pans
and heated from the temperature range of 30°C to 100°C at the heating rate of 20°C/min under an
inert nitrogen atmosphere at a flow rate of 20 mL/min.
3.4 In-vitro dissolution
In-vitro dissolution was carried out using USP (Type I – Basket apparatus) using pH 7.2 phosphate
buffer medium under sink conditions maintained at 37°C according to the USP guidelines. The
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milled extrudates were filled into capsules where a dose equivalent to 50mg of Indo was accurately
weighed into one capsule. The in-vitro dissolution samples were taken at 5, 15, 30, 45, 60, 120
mins and analyzed using reverse phase HPLC method. Analysis was performed using C-18 column
(150mm×4.6 mm, 5 µm), mobile phase of 50:50 acetonitrile and water containing 0.2% phosphoric
acid at 0.8 ml/min flow rate at 254 nm detection wavelength (Nováková, Matysová, Havlíková, &
Solich, 2005).
3.5 Proton and Carbon Nuclear Magnetic Resonance (1H and 13C NMR)
Solution Proton and Carbon Nuclear Magnetic Resonance (1H and 13C NMR) was performed in
an NMR spectrometer (Bruker AM-400 Spectrometer) and used to determine the identity of a
substance and formation of salt by determining the number of hydrogen atoms. Samples in the
present study were dissolved in deuterated DMSO for measurement. NMR spectra were acquired
using a BBI 1H/D-BB Z-GRD probe with a scan number of 16 at 298 K, and the acquisition time
was 1 min and 32 s. In addition, Dept 135 analysis was performed to confirm the salt formation.
3.6 Indomethacin and tromethamine salt preparation
3.6.1 Hot-melt extrusion
The physical blend of Indo and Tro in a 1:1 molar ratio was prepared in a V-Blender for uniform
mixing, and the blend was then fed into a twin screw extruder with screw Configurations depicted
in Figure 49. The operating parameters and conditions were listed in Table 9. During extrusion,
the physical blend converted to the tacky semisolid melt and then formed a thin layer on the inner
contact surface of the extruder barrel. Consequently, much viscous dissipation was created among
the tacky melt, the co-rotating twin screws, and the inner surface of the extruder barrel. Due to the
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conversion of the blend to tacky material during extrusion, it took from 3-7 mins between the
feeding of the blend into the extruder and the exit of the product (residence time).

Temperature
Screw speed
Feed rate
Feed rate
Screw
Formulation
(°C)
(rpm)
(%)
(g/min)
configuration
F-1
135
200
15
3.2
1
F-2
135
200
7
1.6
1
F-3
145
200
7
1.6
1
F-4
135
100
7
1.6
1
F-5
135
100
15
3.2
1
F-6
145
100
7
1.6
1
F-7
145
100
15
3.2
1
F-8
155
100
7
1.6
1
F-9
155
100
15
3.2
1
F-10
135
100
15
3.2
2
Table 9: Extrusion conditions used for preparation of Indo: Tro salts on 11mm Thermo Scientific®

Screw configuration 1

Screw configuration 2

Figure 45 (A): Screw configuration 1 and 2 used for formulation of Indo-Tro salt
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(i) Indomethacin

(ii) Tromethamine

Figure 49 (B): Molecular structure of indomethacin and Tromethamine
3.6.2 Solvent evaporation
1:1 molar ratio of Indo and Tro were accurately weighed and blended using a V-Blender for 15
mins. The physical mixture was added to 200 proof ethanol (not saturated) and stirred using a
magnetic stir bar until complete clear solution was achieved. This solution was rotary evaporated
at 60°C at 200 rpm for 2 hours and dried using a vacuum desiccator until constant weight was
achieved. 1:1 salt of Indo:Tro was thus achieved using solvent evaporation technique.
3.7 FT-NIR study
Diffuse reflectance NIR spectra were continuously collected inline and non-invasively during hotmelt extrusion using a Fourier- Transform NIR spectrometer (Thermo Fisher Scientific, Antaris II
near-IR analyzer) equipped with an InGaAs detector, a quartz halogen lamp, and a fibre-optic
probe which was mounted in the extrusion die. Spectra were collected every 16 s in the 9000–4500
cm-1 region with a resolution of 16 cm-1 and averaged over 8 scans (Wahl et al., 2013).
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4. Results and Discussion
A general idea of the possible mechanism of salt formation by TSE may be obtained from previous
investigations in preparing known co-crystals via TSE, which revealed that co-crystals may be
mediated through eutectic formation. In general, the eutectic melt undergoes super-saturation that
results in crystallization from the melt to form a co-crystal, whose melting is higher than the
eutectic temperature. The phenomenon of eutectic formation can be observed by hot-stage
microscopy.

4.1 FTIR spectroscopy
From Figure 50 (A), the overlay plot of FTIR spectra of pure indomethacin, pure tromethamine,
Indo:Tro 1:1 and Indo:Tro 2:1 blends, obtained by solvent evaporation. Salt formation was
confirmed by the disappearance of the C=O carboxyl functional group at around 1710 cm -1 and
appearance of COO- at 1550 cm-1 in Indo: Tro 1:1, which was not seen in Indo: Tro 2:1 (Coates,
2000). In addition, from figure 50 (B) (C) (D) (E) which corresponds to F-1, F-2, F-3, F-10 hot
melt extrudates, shift of the asymmetric ionized COO- was seen in formulations F-1, F-2, F-10 but
not in F-3. F-3 showed a broad shoulder at 1710 cm-1 indicating presence of crystalline Indo
precipitated from amorphous salt. Thus optimum salt formation was seen when extrusion was
carried out at 135°C.
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Figure 46 (A): Overlay spectra of pure indomethacin, tromethamine, Indo:Tro 1:1 and 2:1 SE
(solvent evaporation) formulation
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Figure 50 (B): FTIR spectra of Indo:Tro hot melt extrudate F-1
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Figure 50 (C): FTIR spectra of Indo:Tro hot melt extrudate F-2
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Figure 50 (D): FTIR spectra of Indo:Tro hot melt extrudate F-3
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Figure 50 (E): FTIR spectra of Indo:Tro hot melt extrudate F-10

4.2 Differential Scanning Calorimetry
The DSC thermograms in Figure 51 (A) shows that Pure Indo melted at 160°C and pure TRO
melted at 148 °C (metastable polymorph) and 174 °C, respectively. The Indo: Tro hot-melt
extrudates, specifically F-1, F-2, F-10 showed endothermic melting events below the individual
melting points. These low “eutectic-like” endothermic events were due to the suppression of Indo
melting in the presence of Tro. The salt obtained by hot-melt extrusion had a melting point of 142
°C which was similar to the melting point of the salt prepared by solvent evaporation (SE). F-3
was observed to be amorphous due to extrusion above the melting temperature of the salt. It also
showed small melting endotherm at 160°C (not seen in image due to overlay) which corresponds
to Indo which might have precipitated out. Also, F-1 and F-2 had comparable enthalpy of melting
compared to F-10 which had greater enthalpy of melting. Figure 51 (B) shows that F-4 was also
crystalline sals of Indo:Tro having a melting point similar to the salt obtained from solvent
evaporation. The lower enthalpy of F-4 compared to the SE salt, which indicates incomplete
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crystallization. Thus it could be concluded that extrusion conditions of high feed rate (3.2g/min),
low screw speed (100 rpm), low temperature (135 °C), low shear screw configuration were
essential for formation of crystalline salt of Indo.

Figure 47 (A): DSC thermograms of Pure Indo, Pure Tro and 1:1 hot melt extrudates

Figure 51 (B): DSC thermograms of Pure Indo, Pure Tro and 1:1 hot melt extrudates
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4.3 X-ray Diffraction
Figure 52 (A) (B) depicts the X-ray diffractograms of crystalline ( F-1, F-2, F-10, SE) and
amorphous (F-3, F-4, F-5, F-6) formulations. It can be seen that the characteristic new 2θ peak at
13.6° for the F-1, F-2, F-10 salt which was not present in the pure components indicates
formulation of a third crystal structure different from Indo and Tro. F-3, F-4, F-5 was observed to
be amorphous due to no Braggs peaks present in the diffractogram. The minimal crystallinity of
F-4 formulation observed in previous DSC data was not detected in XRD study. The maximum
intensity peak was observed with F-10 which implies maximum new crystal content in the
formulation. X-Ray diffraction study confirms with the observation of DSC study (Thakral &
Suryanarayanan, 2015).
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Figure 48 (A) XRD diffractograms of SE salt, F-1,F-2, F-10 crystalline formulation with pure
components
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XRD Plot for Amorphous salts
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Figure 52 (B) XRD diffractograms of F-3, F-4, F-5, F-6 amorphous formulation with pure
components
4.4 In-vitro dissolution
From figure 53 (A) and (B), formulations F1-F3 have >85% in-vitro drug release of in first 15
mins whereas pure Indo and physical mixture only had 5% and 52% release respectively. F-3 had
lower drug release compared to F-1 due to small amount of crystalline indomethacin precipitated
from amorphous salt. Formulations F-4 to F-10 also have >85% in-vitro drug release of in first
15 mins. F-10 had the highest drug release compared to other extruded formulations due to
highest crystalline salt content in the formulation.
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Figure 49 (A): In-vitro dissolution profile of F-1- F-3 extruded formulations

Figure 53 (B): In-vitro dissolution profile of F-4- F-10 extruded formulations
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4.5 NMR spectroscopy
Figure 54 (A, B,C,D) depicts the 1H- NMR spectra of Pure Indo, Pure Tro, SE salt formulation, F2, F-10 and F-3 salt. It can be inferred from the plot that peak for –CH2 group beside the –COOH
carboxylate (refer Figure 49 B) group in the F-1, F-3, SE salt shifts from 3.66 ppm to 3.45 ppm
due to formation of –COO - ion. This indicates formation of salt in the extrudate as well as solvent
evaporated formulation. The peaks for –OCH3 and –CH3 groups in Indo which occur at 3.7 ppm
and 2.19ppm respectively stay constant in the formulations as well. The responses appearing
between 6.5- 7.7 ppm, correspond to aromatic benzene –CH– groups of Indo which also stay
constant in all the formulations. 13C NMR was performed to check for the formation of salt which
would be clearly depicted than 1H- NMR study due to presence of single –CH2 group that needs
to be monitored. From Figure 55 (A, B) it can be observed that the –CH2 and –C=O peak for the
indomethacin which appeared at 29.5 ppm and 172.1ppm shifted to 32.8ppm and 174.4ppm
respectively which indicated ionization of the carboxylic acid group and hence salt formation. Also
135 DEPT analysis was used to confirm the shift of –CH2 group, as indomethacin converts to salt
form (F-10). In 135 DEPT analysis all the –CH2 peaks appear on the bottom of the baseline while
the –CH peaks appear on the top of the baseline. As indomethacin has only one –CH2 it was clearly
depicted by the bottom position of the peak at 29.5ppm. The shift of bottom peak at 29.5ppm to
top peak at 32.8ppm (due to shift of proton from –CH2 to form –CH) was observed as hence salt
formation via extrusion was confirmed.
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Figure 50 (A): 1H- NMR spectroscopy of Pure Indomethacin in DMSO-d6 at 400 Mhz
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Figure 54 (B): 1H- NMR spectroscopy of Pure Tromethamine in DMSO-d6 at 400 Mhz
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Figure 54 (C): 1H- NMR spectroscopy of 1) Pure Indomethacin 2) SE salt in DMSO-d6 at 400
Mhz
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(1)

(2)

(3)

Figure 54 (D): 1H- NMR spectroscopy of 1) F-2 salt 2) F-10 salt 3) F-3 salt in DMSO-d6 at 400
Mhz
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Figure 51 (A): 13C- NMR spectroscopy of Pure Indomethacin in DMSO-d6

87

(1)

(2)

(3)

Figure 55 (B): 13C- NMR spectroscopy(1) Pure Indo, (2) Pure Tro and (3) F-10 salt in DMSO-d6

Figure 55 (C): 135 DEPT analysis of Pure Indomethacin, Pure Tromethamine and F-10 salt
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4.6 FT-NIR study
Diffuse reflectance NIR spectra were continuously collected inline and non-invasively during hotmelt extrusion using a Fourier- Transform NIR spectrometer (Thermo Fisher Scientific, Antaris II
near-IR analyzer) equipped with an InGaAs detector, a quartz halogen lamp, and a fibre-optic
probe which was mounted in the extrusion die (Fig. 2). Spectra were collected every 16 s in the
9000–4500 cm-1 region with a resolution of 16 cm-1 and averaged over 8 scans. Data analysis was
performed using the Result software (Version 3.0, Thermo Fisher Scientific) and TQ Analyst.
Spectra collected in the diffuse reflectance mode mostly require spectral pre-treatment before
analysis. The degree of scattering depends on the wavelength of the light and the refractive index
of the sample, which causes a non-equal scatter over the whole spectrum. This can result in a
baseline shift. Therefore, multiplicative signal correction (MSC) was used before chemometric
analysis of the spectra. Using MSC, undesired scatter is removed from the raw spectra to prevent
it from dominating over the chemical information within the spectra. The result of MSC preprocessing is that each corrected spectrum has the same offset and amplitude, eliminating the
difference in light scatter in the spectra from the different samples, before developing the
calibration model. Furthermore, second derivative pre-processing was done after MSC correction.
Second derivatives of NIR spectra magnify differences in spectral features provide baseline
normalization and remove data offsets due to scattering effects and pathlength variation (Saerens
et al., 2012).
Figure 56 describes the FT-NIR spectra of pure indomethacin and pure tromethamine powders at
room temperature. The peak at 6500 cm-1 is characteristic of the amine group of Tro and the peak
at 5900 cm-1 is characteristic of the carboxylate group of Indo.
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Figure 52: FT-NIR spectra of Indomethacin and tromethamine powders at room temperature

Figure 57 depicts the FT-NIR spectra of melting process of pure tromethamine. It can be noted
that there is gradual increase in the intensity and sharp peak of amine group at 6500 cm-1. Also
there is gradual appearance of the –OH peak at 7000 cm-1 at the melting process proceeds, which
might be due to breaking of intra-molecular H-bonding in the Tro salt and hence availability of –
OH groups.
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Figure 53: FT-NIR spectra of melting process of pure tromethamine
Figure 58 demonstrates the FT-NIR spectra of melting process of pure indomethacin. Here the
peak corresponding to carboxylate group at 5900 cm-1 diminishes in size due to temporary
amorphization in the melted state.

Figure 54: FT-NIR spectra of melting process of pure indomethacin
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Figure 59 shows the overlay of the spectra of the melted forms of Indo and Tro respectively. Here
it can be seen that the peaks of interest of Indo (5900cm-1) and Tro (6500 cm-1) can be selected for
analyzing the salt formation as they do not overlap in the other spectra and hence characteristic to
model interaction.
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Figure 55: Comparison of Indomethacin and tromethamine hot-melts

Figure 60 shows the real time in-line data collected from the Antaris II probe. At 135oC, the hot
melt has opaque salt form of particles. The scattering from solid particles generated strong
reflectance signal (low spectral baseline) and short penetration distance (low peak height). The hot
melt became clear liquid at 145oC and above, and the large baseline drift was the result of weak
reflection signal.
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In Figure 61, the spectral peak area at 5900 cm-1 was used for the penetration distance or
pathlength correction. Since this peak is mainly the response from Indomethacin, the normalized
spectra will more relate to per unit weight of Indomethacin.

Figure 57: Spectral pathlength normalization
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Figure 62 After application of Norris derivative to the spectral region of interest, the spectral
variation in the intensity of the amine peak and the carboxylate group could be monitored. A
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Figure 58: Second Norris derivative of complete FT-NIR spectra
Figure 63 depicts the calibration of the Partial Least Square (PLS) model used to determine the
correlation between the % crystalline salt formation and peak intensity from 6100 cm-1 to 5800
cm-1. The lesser intensity of carboxylate peak at lower temperature (135°C) implied greater
crystalline salt formation reaction compared to higher temperature extrudates (145°C and above)
where the interaction resulted in amorphous salt formation. From the calibration we could achieve
a co-relation of greater than 95%. The crystalline salts achieved from F-1, F-2, F-4 and F-10 were
analyzed and the % crystallinity mentioned in Table 10. F-10 was the formulation with greatest
crystalline salt formation.
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Figure 59: Calibration of the peak intensity from 6100 cm-1- 5800 cm-1

Formulation
F-1
F-2
F-3
F-4
F-5
F-6
F-7
F-8
F-9
F-10

Temperature
(°C)
135
135
145
135
135
145
145
155
155
135

Screw speed
(rpm)
200
200
200
100
100
100
100
100
100
100

Crystalline
salt (%)
75.8
80.5
50.1
98.5

Feed rate
(g/min)
3.2
1.6
1.6
1.6
3.2
1.6
3.2
1.6
3.2
3.2

Screw
configuration
1
1
1
1
1
1
1
1
1
2

Table 10: % Crystalline salt formation of Indomethacin and Tromethamine at different extrusion
conditions
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5. Conclusion
Salt formation of a poorly water soluble compound was successfully achieved using hot-melt
extrusion. The product characteristics were evaluated using in-line FT-NIR and other solid state
characterization tools to better understand the influence of processing parameters. The extrusion
condition of feed rate 3.2g/min, 100 rpm, 135 °C screw configuration 2 resulted in highest
crystalline salt formation of 98.5% crystallinity. The extrusion at 145 °C and above resulted in
amorphization of the API and resulting salt formulation. It could be concluded that temperature
and shear stress were the two significant parameters to affect the product quality. At higher
temperature and shear stress (by increasing kneading blocks in screw configuration and screw
speed) resulted in breakdown of the possible crystalline nature of the salt. In-line FT-NIR was
successfully applied as a PAT tool to detect the optimal processing conditions for salt formation
using hot-melt extrusion process.

96

BIBLIOGRAPHY

97

Aakeröy, C. B., Fasulo, M. E., & Desper, J. (2007). Cocrystal or salt: does it really matter?
Molecular Pharmaceutics, 4(3), 317-322.
Bahloul, B., Lassoued, M. A., & Sfar, S. (2014). A novel approach for the development and
optimization of self emulsifying drug delivery system using HLB and response surface
methodology: application to fenofibrate encapsulation. International journal of
pharmaceutics, 466(1), 341-348.
Balakrishnan, P., Lee, B.-J., Oh, D. H., Kim, J. O., Hong, M. J., Jee, J.-P., . . . Yong, C. S. (2009).
Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug
delivery system (SEDDS). European Journal of Pharmaceutics and Biopharmaceutics,
72(3), 539-545.
Bari, H. C., Doijad, R. C., More, H. N., & Disouza, J. I. (2011). Design and optimization of
chlordiazepoxide solid self-microemulsifying drug delivery system. J Pharm Res, 4(2),
369-372.
Berge, S. M., Bighley, L. D., & Monkhouse, D. C. (1977). Pharmaceutical salts. Journal of
pharmaceutical sciences, 66(1), 1-19.
Bika, D., Tardos, G., Panmai, S., Farber, L., & Michaels, J. (2005). Strength and morphology of
solid bridges in dry granules of pharmaceutical powders. Powder Technology, 150(2), 104116.
Coates, J. (2000). Interpretation of infrared spectra, a practical approach. Encyclopedia of
analytical chemistry.
Cole, E. T., Cadé, D., & Benameur, H. (2008). Challenges and opportunities in the encapsulation
of liquid and semi-solid formulations into capsules for oral administration. Advanced drug
delivery reviews, 60(6), 747-756.
Dixit, R. P., & Nagarsenker, M. (2010). Optimized microemulsions and solid microemulsion
systems of simvastatin: characterization and in vivo evaluation. Journal of pharmaceutical
sciences, 99(12), 4892-4902.
Gumaste, S. G., Pawlak, S. A., Dalrymple, D. M., Nider, C. J., Trombetta, L. D., & Serajuddin, A.
T. (2013). Development of solid SEDDS, IV: effect of adsorbed lipid and surfactant on
98

tableting properties and surface structures of different silicates. Pharmaceutical research,
30(12), 3170-3185.
Gupta, V., Hwang, B. H., Doshi, N., & Mitragotri, S. (2013). A permeation enhancer for increasing
transport of therapeutic macromolecules across the intestine. Journal of controlled release,
172(2), 541-549.
Kim, D. W., Kang, J. H., Oh, D. H., Yong, C. S., & Choi, H.-G. (2012). Development of novel
flurbiprofen-loaded solid self-microemulsifying drug delivery system using gelatin as solid
carrier. Journal of microencapsulation, 29(4), 323-330.
Kocbek, P., Baumgartner, S., & Kristl, J. (2006). Preparation and evaluation of nanosuspensions
for enhancing the dissolution of poorly soluble drugs. International journal of
pharmaceutics, 312(1), 179-186.
Lee, H. L., Vasoya, J. M., Cirqueira, M. d. L., Yeh, K. L., Lee, T., & Serajuddin, A. T. (2017).
Continuous Preparation of 1: 1 Haloperidol–Maleic Acid Salt by a Novel Solvent-Free
Method Using a Twin Screw Melt Extruder. Molecular Pharmaceutics, 14(4), 1278-1291.
Mu, B., & Thompson, M. (2012). Examining the mechanics of granulation with a hot melt binder
in a twin-screw extruder. Chemical engineering science, 81, 46-56.
Nie, H., Xu, W., Ren, J., Taylor, L. S., Marsac, P. J., John, C. T., & Byrn, S. R. (2016). Impact of
metallic stearates on disproportionation of hydrochloride salts of weak bases in solid-state
formulations. Molecular Pharmaceutics, 13(10), 3541-3552.
Nováková, L., Matysová, L., Havlíková, L., & Solich, P. (2005). Development and validation of
HPLC method for determination of indomethacin and its two degradation products in
topical gel. Journal of pharmaceutical and biomedical analysis, 37(5), 899-905.
Park, J.-B., Lee, B.-J., Kang, C.-Y., Tiwari, R. V., & Repka, M. A. (2017). Process analytical
quality control of tailored drug release formulation prepared via hot-melt extrusion
technology. Journal of Drug Delivery Science and Technology, 38, 51-58.
Patel, D. P., Li, P., & Serajuddin, A. T. (2016). Enhanced microemulsion formation in lipid-based
drug delivery systems by combining mono-esters of mediumchain fatty acids with di-or
tri-esters. Journal of Excipients and Food Chemicals, 3(2).
99

Patil, H., Tiwari, R. V., Upadhye, S. B., Vladyka, R. S., & Repka, M. A. (2015). Formulation and
development of pH-independent/dependent sustained release matrix tablets of ondansetron
HCl by a continuous twin-screw melt granulation process. International journal of
pharmaceutics, 496(1), 33-41.
Pudipeddi, M., Serajuddin, A., Grant, D., & Stahl, P. (2002). Solubility and dissolution of weak
acids, bases, and salts. Handbook of Pharmaceutical Salts, Properties, Selection, and Use.
Zurich, Switzerland: Verlag Helvetica Chimica Acta and Weinheim, Wiley-VCH,
Weinheim, Federal Republic of Germany: Wiley-VCH, 19-39.
Pudlas, M., Kyeremateng, S. O., Williams, L. A., Kimber, J. A., van Lishaut, H., Kazarian, S. G.,
& Woehrle, G. H. (2015). Analyzing the impact of different excipients on drug release
behavior in hot-melt extrusion formulations using FTIR spectroscopic imaging. European
Journal of Pharmaceutical Sciences, 67, 21-31.
Qian, F., Huang, J., & Hussain, M. A. (2010). Drug–polymer solubility and miscibility: stability
consideration and practical challenges in amorphous solid dispersion development. Journal
of pharmaceutical sciences, 99(7), 2941-2947.
Qiao, N., Wang, K., Schlindwein, W., Davies, A., & Li, M. (2013). In situ monitoring of
carbamazepine–nicotinamide cocrystal intrinsic dissolution behaviour. European Journal
of Pharmaceutics and Biopharmaceutics, 83(3), 415-426.
Rajput, L. (2014). Stable crystalline salts of haloperidol: A highly water-soluble mesylate salt.
Crystal Growth & Design, 14(10), 5196-5205.
Saerens, L., Dierickx, L., Quinten, T., Adriaensens, P., Carleer, R., Vervaet, C., . . . De Beer, T.
(2012). In-line NIR spectroscopy for the understanding of polymer–drug interaction during
pharmaceutical

hot-melt

extrusion.

European

Journal

of

Pharmaceutics

and

Biopharmaceutics, 81(1), 230-237.
Saxena, V., & Hussain, M. D. (2012). Poloxamer 407/TPGS mixed micelles for delivery of
gambogic acid to breast and multidrug-resistant cancer. International journal of
nanomedicine, 7, 713.

100

Schilling, S. U., & McGinity, J. W. (2010). Novel application of hot-melt extrusion for the
preparation of monolithic matrices containing enteric-coated particles. International
journal of pharmaceutics, 400(1), 24-31.
Schmolka, I. R. (1977). A review of block polymer surfactants. Journal of the American Oil
Chemists' Society, 54(3), 110-116.
Serajuddin, A. T. (1999). Solid dispersion of poorly water soluble drugs: Early promises,
subsequent problems, and recent breakthroughs. Journal of pharmaceutical sciences,
88(10), 1058-1066.
Sha, X., Yan, G., Wu, Y., Li, J., & Fang, X. (2005). Effect of self-microemulsifying drug delivery
systems containing Labrasol on tight junctions in Caco-2 cells. European Journal of
Pharmaceutical Sciences, 24(5), 477-486.
Shah, A. V., & Serajuddin, A. T. (2012). Development of solid self-emulsifying drug delivery
system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for
lipids. Pharmaceutical research, 29(10), 2817-2832.
Stephenson, G. A., Aburub, A., & Woods, T. A. (2011). Physical stability of salts of weak bases
in the solid state. Journal of pharmaceutical sciences, 100(5), 1607-1617.
Thakral, S., & Suryanarayanan, R. (2015). Salt formation during freeze-drying-an approach to
enhance indomethacin dissolution. Pharmaceutical research, 32(11), 3722-3731.
Vasanthavada, M., Wang, Y., Haefele, T., Lakshman, J. P., Mone, M., Tong, W., . . . Abu, T.
(2011). Application of melt granulation technology using twin screw extruder in
development

of

high dose

modified release

tablet

formulation.

Journal

of

pharmaceutical sciences, 100(5), 1923-1934.
Wahl, P. R., Treffer, D., Mohr, S., Roblegg, E., Koscher, G., & Khinast, J. G. (2013). Inline
monitoring and a PAT strategy for pharmaceutical hot melt extrusion. International journal
of pharmaceutics, 455(1), 159-168.

101

VITA

Priyanka Thipsay
EDUCATION
Doctor of Philosophy (Ph.D.) Pharmaceutics
Aug 2018
University of Mississippi (UM), GPA: 3.92/4.0
Dissertation: Application of Design of Experiments (DOE) and Process Analytical Technology
(PAT) towards Pharmaceutical extrusion processes. (Advisor: Dr. Michael Repka)
M.S. Industrial Pharmacy
Aug 2013
St. John’s University, NY, GPA: 3.8/4.0
Thesis: Ionic Liquid: A Novel Approach for Improving the Dissolution Rate of a Poorly Water Soluble
Drug.
Bachelor of Science (B.S.) in Pharmacy
University of Mumbai, India, GPA: 3.7/4.0

May 2010

PROFESSIONAL EXPERIENCE
Patheon Pharmaceuticals, OH, USA
Sr. Scientist I (Pharmaceutics & Process Technology)

Apr 2018-current

AbbVie Inc., Lake county, IL, USA
May 2016- Aug 2016
Graduate Summer Intern (Manufacturing Science & Technology, Oral drug products)
Hands-on course in tablet technology at University of Mississippi
Lab instructor

Sept 2014 – Dec 2017

AWARDS AND HONORS
Travelship for 11th World meeting Pharmaceutics, Biopharm., Pham. Technology, Spain Mar 2018
Texture Technologies® sponsored scholarship, AAPS 2017-AM
Oct 2017
Dissertation fellowship, Dept. of Pharmaceutics, University of Mississippi
Nov 2017
Manufacturing Science & Engineering section Travelship Award for best poster, AAPS Aug 2016
Amgen sponsored Graduate Student Travelship Award for best poster, AAPS
Oct 2015
Best Graduate Poster Award, 4th place Society of Plastic Engineering (SPE) conference Mar 2015
Honor Member, Rho-Chi Society, University of Mississippi
Jan 2015
Astra Zeneca sponsored Graduate Student Travelship Award for best poster, AAPS
Nov 2014
Scholarship for “Excellence in Academics” by Pfizer (I) Ltd, Mumbai
Sept 2006
102

LEADERSHIP
University of Mississippi (UM)-AAPS student chapter
Chairperson
AAPS Annual meeting 2013, San Antonio
Co-moderator
St. John’s University -AAPS student chapter
Treasurer

Sept 2014- Sept 2017
Nov 2013
Sept 2010-Aug 2011

PROFESSIONAL PRESENTATIONS
 P.Thipsay, M.A.Repka; Effect of different HPMC grades and process parameters on physicochemical properties of sustained release matrix granules prepared via twin screw melt granulation
Nov 2017
 R. Lalge, P.Thipsay, M.A. Repka et.al. Cefuroxime Axetil Gastroretentive Floating Drug Delivery
System Prepared by Hot-Melt Extrusion for Improved bioavailability
Nov 2017
 P.Thipsay, M.A. Repka et al. “Formulation, evaluation and optimization of biodegradable polymeric
implants prepared by hot-melt extrusion process” AAPS annual conference
Oct 2015
 P.Thipsay, M.A. Repka et al. “Formulation of solid self-microemulsions using hot melt extrusion
technology” at SPE annual technical conference, Orlando
Mar 2015
 P.Thipsay, M.A. Repka et al. “ Bioadhesive drug delivery system for enhancing bioavailability of BCS
class III drug by hot-melt extrusion technology” at AAPS annual conference, Orlando
Oct 2015
 P.Thipsay, M.A. Repka et al. “ Hot melt extrusion technology for the formulation of Solid SMEDDS” at
AAPS annual conference, San Diego
Nov 2014
 P.Thipsay, E. Squillante et al. “Formulation of Ionic liquid to improve dissolution rate” at AAPS annual
conference, San Antonio
Nov 2013

PUBLICATIONS
 A. Bhagurkar, P. Thipsay, M.A. Repka; Effects of formulation composition on the
characteristics of mucoadhesive films prepared by hot-melt extrusion technology, Journal of
Pharmacy and Pharmacology, Nov 2018
 M. Bookwala, P.Thipsay, M.A.Repka; Preparation of a Crystalline Salt of Indomethacin and
Tromethamine by Hot Melt Extrusion Technology, Eur. J. of Pharmaceutics and
Biopharmaceutics, Aug 2018
 N. Mendonsa, P. Thipsay, M.A. Repka; Bioadhesive Drug Delivery System for Enhancing the
Permeability of a BCS Class III Drug via Hot-Melt Extrusion Technology, AAPS Pharm Sci Tech
Feb 2017
 A. Gandhi, B. Kirthivasan, P.Thipsay, E. Squillante; Adsorption on mesoporous silica using
supercritical fluid technology improves dissolution rate of Carbamazepine: A poorly soluble
compound, AAPS Pharm Sci Tech, Aug 2017.

103

